Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The South African regulator, SAHPRA, said that it requested “data demonstrating the safety of the Sputnik V vaccine in settings of high HIV prevalence and incidence” but the local license-holder for the...
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...‘Perfect scenario’ Those look like V-shaped projections, Andrew Glenn thought to himself....
...This is particularly true in the case of messenger RNA vaccines, such as those made by Moderna and Pfizer, which use genetic code made by a biological process and involve technology that is not easily replicated...
...Berenberg analyst Adrian Yanoshik noted that, “as a shareholder or even a debt-holder, if you have cash in the door, and it’s being used, you want that cash to be used to the highest return possible, and...
...It gave the job to Pfizer, the US pharmaceutical company, which it seems messed it up....
...In December, GSK said it was hiving off its consumer division and debt into a joint venture with Pfizer....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...Related links: Shared mobility V.1, USSR edition – FT Alphaville Do the economics of self-driving taxis actually make sense? – FT Alphaville Who are Tesla’s competitors, really?...
...Its new Class V shares will represent some 65 per cent of its stake in VMware — though holders will have no direct rights in VMware, and Dell will have the right to switch the underlying assets and businesses...
...Sanofi and Aventis merged to take on US pharma, but have not caught Pfizer. Nor have Glaxo and SmithKline Beecham....
...While the Patent Act “unambiguously permits a patent holder to recover the infringer’s entire profits from the ‘article of manufacture’ to which the design was applied”, the DoJ cautioned that the “‘article...
...The top 50 holders accounted for $1.1tn of that amount....
...electronics company is making a last-ditch effort to overturn a ruling that it says applies patent law too broadly and could impede competition in the technology market by awarding “excessive” damages to patent holders...
...Chairman Leif Johansson triggered a paper loss last year when he rebuffed a £55-a-share bid from Pfizer. The shares remain £10 cheaper....
...Also: AR v VR Do you like your reality augmented or completely virtual? Augmented reality has seen little progress with no sign yet of Google bringing out the next generation of Google Glass....
...A similar principle was established for utility patents by the Supreme Court in the case of Markman v Westview Instruments in 1996....
...Will AstraZeneca’s board be making a mistake if they definitively reject Pfizer’s offer? Oh, yes. Start with the money. Pfizer is offering £69bn, £31bn of that in cash....
...(Financial Times) Pfizer snub triggers recrimination at Astra: “Pfizer’s pursuit of AstraZeneca was hanging by a thread on Monday after its “final” £69.4bn offer was rejected by the UK company, sparking...
...Pharmaceutical company Pfizer’s proposed £69bn takeover of UK rival AstraZeneca may have come to an end, for now at least, but its repercussions rumble on....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“It is clearly very unhelpful for holders of Shire shares. Shire is right to insist that the deal should go ahead. This has certainly come as a shock....
International Edition